Market capitalization | $1.15m |
Enterprise Value | $1.44m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 0.59 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-6.37m |
Free Cash Flow (TTM) Free Cash Flow | $-2.69m |
Cash position | $190.00k |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast 180 Life Sciences Corp:
1 Analyst has issued a forecast 180 Life Sciences Corp:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.08 -0.08 |
33%
33%
|
|
EBITDA | -6.29 -6.29 |
64%
64%
|
EBIT (Operating Income) EBIT | -6.37 -6.37 |
64%
64%
|
Net Profit | -3.12 -3.12 |
92%
92%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
180 Life Sciences Corp. develops pharmaceuticals for chronic pain and inflammatory diseases. It operates as a clinical-stage biotechnology company focused on the development of novel drugs that fulfil unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded in 2016 and is headquartered in Menlo Park, CA.
Head office | United States |
CEO | Blair Jordan |
Employees | 4 |
Founded | 2016 |
Website | www.180lifesciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.